Cytokinetics' hopes of resurrecting cardiac myosin activator omecamtiv mecarbil have suffered another setback, after the drug failed to show a benefit in a phase 3 heart failure study. In the ...

Oct. 16, 2024 (GLOBE NEWSWIRE) -- Cytokinetics, Incorporated (Nasdaq: CYTK) will provide an update on the company’s cardiac myosin modulation programs and global commercial launch readiness for ...

Cytokinetics, Bayer enter collaboration and licensing pact to develop & commercialize aficamten in Japan: South San Francisco, California Wednesday, November 20, 2024, 15:00 Hrs [ ...

Analysing Cytokinetics' potential in the biopharma market with its drug aficamten, projected peak sales of $3.6 billion and ...

Approximately €70 Million in Upfront and Near-term Payments to Cytokinetics Up to €490 Million in Commercial Milestone ...

California, USA-based biotech Cytokinetics saw its shares fall as much as 4% to $9.67 yesterday, after it announced a deal ...

No biological system has been studied by more diverse approaches than the actin-based molecular motor myosin. Biophysics, biochemistry, physiology, classical genetics and molecular genetics have ...

Bayer BAYRY announced that the FDA has accepted its supplemental new drug application (sNDA) for Nubeqa (darolutamide). The ...

Bayer AG BAYRY announced that it will acquire rights to the late-stage specialty cardiovascular biopharmaceutical company ...

Bristol Myers Squibb Canada (BMS) is proud to announce that CAMZYOS™ (mavacamten capsules) has been named the 2024 winner of ...

Don't Miss our Black Friday Offers: Joseph Pantginis has given his Buy rating due to a combination of factors stemming from the positive clinical outcomes associated with Cytokinetics’s cardiac myosin ...

Discover the impact of hypereosinophilia on heart health, focusing on eosinophilic heart disease (EHD) and its mechanisms.